Abbreviated product information

multi**Bic®** potassium-free, Solution for Haemofiltration
multi**Bic®** 3 mmol/L potassium, Solution for Haemofiltration
multi**Bic®** 2 mmol/L potassium, Solution for Haemofiltration
multi**Bic®** 4 mmol/L potassium, Solution for Haemofiltration

multi**Bic®** potassium-free/2/3/4 mmol/L potassium is delivered in a double-chamber bag. One chamber (large compartment) contains the alkaline hydrogen carbonate solution, the other chamber (small compartment) contains the acidic glucose-based electrolyte solution. Mixing of both solutions by opening the peel seam between the two chambers results in the ready-to-use solution.

Composition: 1000 mL of the ready-to-use solution contain:

Active substances in [g/L]:	multi**Bic®** **potassium-free**	multi**Bic®** **2 mmol/L potassium**	multi**Bic®** **3 mmol/L potassium**	multi**Bic®** **4 mmol/L potassium**
Sodium chloride	6.136	6.136	6.136	6.136
Potassium chloride	–	0.1491	0.2237	0.2982
Sodium hydrogen carbonate	2.940	2.940	2.940	2.940
Calcium chloride dihydrate	0.2205	0.2205	0.2205	0.2205
Magnesium chloride hexahydrate	0.1017	0.1017	0.1017	0.1017
Glucose monohydrate = equivalent to glucose	1.100 1.000	1.100 1.000	1.100 1.000	1.100 1.000

1000 mL of the ready-to-use solution contain:

Active substances in [mmol/L]:	multi**Bic®** **potassium-free**	multi**Bic®** **2 mmol/L potassium**	multi**Bic®** **3 mmol/L potassium**	multi**Bic®** **4 mmol/L potassium**
Na^+	140	140	140	140
K^+	–	2.0	3.0	4.0
Ca^{++}	1.5	1.5	1.5	1.5
Mg^{++}	0.50	0.50	0.50	0.50
Cl^-	109	111	112	113
HCO_3^-	35	35	35	35
Glucose	5.55	5.55	5.55	5.55
Theoretical osmolarity [mosm/L]	292	296	298	300
pH ≈ 7.2				

Excipients: Water for injections, hydrochloric acid (25 %), carbon dioxide.

Indications: For use in patients with acute renal failure requiring continuous haemofiltration.

Contraindications: Solution dependent contraindications: multi**Bic®** potassium-free/2/3 mmol/L potassium: hypokalaemia, metabolic alkalosis; multi**Bic®** 4 mmol/L potassium: hyperkalaemia, metabolic alkalosis; Haemofiltration dependent contraindications due to the technical procedure itself: Renal failure with increased hypercatabolism in cases where uraemic symptoms can no longer be relieved by haemofiltration; Inadequate blood flow from vascular access; If there is a high risk of haemorrhage on account of systemic anticoagulation.

Side effects: Adverse reactions, such as nausea, vomiting, muscle cramps, hypotension and hypertension, may result from the treatment mode itself or may be induced by the substitution solution. In general, the tolerability of bicarbonate buffered haemofiltration solution is good. However, the following potential side effects of the treatment can be anticipated: Hyper- or hypohydration, electrolyte disturbances (e. g. hypokalaemia), hypophosphataemia, hyperglycaemia, and metabolic alkalosis.

Warnings and Precautions: Do not use unless solution is clear and the container is undamaged. Do not use before the two solutions have been mixed. The ready-to-use solution shall be used immediately, not be stored above +25 °C and must be used within a maximum of 48 hours after mixing. Any unused residual solution should be discarded. Do not store below +4 °C.

Date: April 2012.

Fresenius Medical Care Deutschland GmbH, 61346 Bad Homburg v.d.H., Germany

FRESENIUS
MEDICAL CARE

Head office: Fresenius Medical Care Deutschland GmbH · 61346 Bad Homburg v. d. H. · Germany
Phone: +49 (0) 6172-609-0 · Fax: +49 (0) 6172-609-2191
www.fmc-ag.com

F00004881 GB (0.5 BG-HMD 02.13)